Are peroxisome proliferator-activated receptors new therapeutic targets in diabetic and non-diabetic nephropathies?

Helbich T, Tscholakoff D. Polyetiology of renal allograft dysfunction. Does calculation of the resistive index still make sense? Acta Radiol 1992; 33: 434–439 7. Scholbach T, Girelli E, Scholbach J. Dynamic tissue perfusion measurement: a novel tool in follow-up of renal transplants. Transplantation 2005; 79: 1711–1716 8. Nankivell BJ, Chapman JR, Gruenewald SM. Detection of chronic allograft nephropathy by quantitative doppler imaging. Transplantation 2002; 74: 90–96 9. Jakobsen JA, Oyen R, Thomsen HS, Morcos SK. Safety of ultrasound contrast agents. Eur Radiol 2005; 15: 941–945 10. Albrecht T, Blomley M, Bolondi L et al. Guidelines for the use of contrast agents in ultrasound. Ultraschall Med 2004; 25: 249–256 11. Korosoglou G, Hansen A, Hoffend J et al. Comparison of realtime myocardial contrast echocardiography for the assessment of myocardial viability with fluorodeoxyglucose-18 positron emission tomography and dobutamine stress echocardiography. Am J Cardiol 2004; 94: 570–576 12. Lindner JR, Villanueva FS, Dent JM, Wei K, Sklenar J, Kaul S. Assessment of resting perfusion with myocardial contrast echocardiography: theoretical and practical considerations. Am Heart J 2000; 139(2 Pt 1): 231–240